FCA Venture Partners was founded to back early-stage healthcare companies with practical, operator-driven support—not just capital. The core thesis is that healthcare’s complexity creates opportunity for disciplined investors who understand providers, payers, pharma services, and care delivery models. We focus on late-seed through Series B companies where we can lead or co-lead rounds, typically investing $2–4 million initially. We prioritize capital-efficient models, strong founders with domain depth, and businesses positioned to scale through measurable ROI, recurring revenue, and clear paths to strategic or private equity exits.
Founders choose FCA because we bring more than a check—we bring context, relationships, and hands-on partnership. We’ve spent years building credibility across health systems, payers, and pharma, which translates into real customer introductions and strategic guidance. We have 10 strategic LP’s and hope to add to that in the future. We understand how to navigate reimbursement, regulatory complexity, and enterprise sales cycles. At our size, every investment matters, so companies get senior-level attention and long-term alignment rather than being one of many small bets in a large platform fund.
Over the next 12 months, our primary goal is to successfully raise and deploy capital from our new healthcare-focused fund, FCA Health Innovations III, while continuing to support portfolio companies toward meaningful value inflection points and liquidity events. Success means adding high-quality healthcare executive and strategic LPs (reach out to me if you’re interested in learning more), while raising enough capital so that we can make 25 new investments that fit our thesis. We also define success as driving operational progress within existing portfolio companies—improving revenue growth, capital efficiency, and positioning select assets for exit or follow-on financing.